• Caffeine
  • By administering dihydroergotamine alone (or a combination of DHE and caffeine) major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses. (google.com)
  • inhibitors
  • Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. (goodrx.com)
  • inhibition
  • Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. (goodrx.com)